Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®
-
Published Date:
10/26/12
-
Series:HAN ; 331
-
Language:English
-
[PDF-1.09 MB]
Details:
-
Corporate Authors:
-
Description:October 26, 2012, 18:00 ET (6:00 PM ET) CDCHAN-00331-2012-26-10-UPD-N The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing. This HAN notice provides information on the following: • Status of the investigation • Background on T T P and Opana ER® • Recommendations • Case definition
-
Subject:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:No Additional Files
No Related Documents.
Email
CDC-INFO
